1.08
+0.05(+4.85%)
Currency In USD
| Previous Close | 1.03 |
| Open | 1.05 |
| Day High | 1.09 |
| Day Low | 1.05 |
| 52-Week High | 1.89 |
| 52-Week Low | 0.92 |
| Volume | 187,259 |
| Average Volume | 290,116 |
| Market Cap | 58.88M |
| PE | 13.5 |
| EPS | 0.08 |
| Moving Average 50 Days | 1.17 |
| Moving Average 200 Days | 1.36 |
| Change | 0.05 |
If you invested $1000 in Spero Therapeutics, Inc. (SPRO) since IPO date, it would be worth $93.91 as of January 03, 2025 at a share price of $1.08. Whereas If you bought $1000 worth of Spero Therapeutics, Inc. (SPRO) shares 5 years ago, it would be worth $112.73 as of January 03, 2025 at a share price of $1.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024
GlobeNewswire Inc.
Nov 07, 2024 9:05 PM GMT
CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update
GlobeNewswire Inc.
Oct 29, 2024 8:05 PM GMT
Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients Phase 3 PIVOT-PO trial of tebipenem HBr remains
Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024
GlobeNewswire Inc.
Oct 16, 2024 8:05 PM GMT
In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents Study highlighting SPR720 potential benefits for prolonged combination re